Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol 2025; 46(01): 087-092
DOI: 10.1055/s-0044-1792008
Original Article

Role of Cell-Free DNA in Relapsed Head and Neck Cancer

Annie Kanchan Baa
1   Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Atul Sharma 
1   Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Mayank Singh 
1   Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Ashna Gupta
1   Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Ahitagni Biswas
2   Department of Radiation Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Sacchidanand Jee Bharti
3   Department of Oncoanesthesia and Palliative Medicine, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Alok Thakar
4   Department of Head and Neck Surgery, All India Institute of Medical Sciences, New Delhi, India
,
Rajeev Kumar
4   Department of Head and Neck Surgery, All India Institute of Medical Sciences, New Delhi, India
,
Raja Pramanik 
1   Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction Owing to the aggressive biology of head and neck squamous cell carcinoma (HNSCC), new biomarkers that can facilitate the diagnosis and tracking of tumour growth are the need of the hour. Liquid biopsy has emerged as an easier tool than tissue biopsy to monitor the emergence of treatment resistance or the recurrence of disease at the molecular level.

Objectives To assess the role of cell-free DNA (cfDNA) as a biomarker for relapsed HNSCC.

Materials and Methods This study is a Phase 2 interventional study (NCT: CTRI/2020/02/023378) that assessed the response rates of a new triplet drug regimen in refractory or relapsed HNSCC. Thirty-five patients underwent blood sampling before the commencement of therapy and at 3 months of treatment. Isolation of cfDNA was done using magnetic beads (molecular weight near 170 kb) for quantification.

Results Twenty-eight patients had comparable data at baseline and after 3 months of treatment. The mean cfDNA reading at baseline was 8.9 ng/μL (range: 2.6 -7.3 ng/μL) of blood. The cfDNA concordance with clinical and radiological outcomes was 54.2%. The patients who responded to therapy were compared over time with patients who did not respond. Repeated measures testing found a significant difference (p 1?4 0.0035) in changes to the cfDNA levels of these two groups.

Conclusion This study posits the potential value of liquid biopsy in the treatment of recurrent HNSCC. Our findings prove the clinical relevance as well as limitations of cfDNA, which warrant extrapolation in an upfront setting too.

Keywords

molecular biomarker - recurrence risk - resistance - cell-free DNA - head and neck tumors - liquid biopsy - mutations

Patient Consent

Patient consent was obtained for this study.




Publication History

Article published online:
13 December 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Patil VM, Noronha V, Joshi A. et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol 2015; 51 (03) 279-286
    CrossrefPubMedSearch in Google Scholar
  • 2 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    CrossrefPubMedSearch in Google Scholar
  • 3 Singhal A, Hussain A, Agarwal A, Thakur B. Current status of cell-free DNA in head and neck cancer management. Annals of Indian Academy of Otorhinolaryngology Head and Neck Surgery 3 (01) 1-7
  • 4 Kong L, Birkeland AC. Liquid biopsies in head and neck cancer: current state and future challenges. Cancers (Basel) 2021; 13 (08) 1-16
    CrossrefPubMedSearch in Google Scholar
  • 5 Wan JCM, Massie C, Garcia-Corbacho J. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017; 17 (04) 223-238
    CrossrefPubMedSearch in Google Scholar
  • 6 Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11 (06) 426-437
    CrossrefPubMedSearch in Google Scholar
  • 7 Tokuhisa Y, Iizuka N, Sakaida I. et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007; 97 (10) 1399-1403
    CrossrefPubMedSearch in Google Scholar
  • 8 Palmirotta R, Lovero D, Cafforio P. et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol 2018; 10: 1758835918794630
    CrossrefPubMedSearch in Google Scholar
  • 9 Brandt A, Thiele B, Schultheiß C, Daetwyler E, Binder M. Circulating tumor DNA in head and neck squamous cell carcinoma. Cancers (Basel) 2023; 15 (07) 15
    CrossrefPubMedSearch in Google Scholar
  • 10 Baa AK, Sharma A, Bhaskar S. et al. A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ecancermedicalscience 2022; 16: 1451
    PubMedSearch in Google Scholar
  • 11 Baa AK, Sharma A, Bhaskar S. et al. Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Ecancermedicalscience 2023; 17: 1578
    PubMedSearch in Google Scholar
  • 12 Surani A., Poterlowicz K.. (2016) “Circulating tumour DNA: a minimally invasive biomarker for tumour detection and stratification”, British Journal of Pharmacy. 1 (01) 3-18
  • 13 Lin LH, Chang KW, Kao SY, Cheng HW, Liu CJ. Increased plasma circulating cell-free DNA could be a potential marker for oral cancer. Int J Mol Sci 2018; 19 (11) 19
    CrossrefPubMedSearch in Google Scholar
  • 14 Verma T, Kumari S, Mishra S. et al. Circulating free DNA as a marker of response to chemoradiation in locally advanced head and neck squamous cell carcinoma. Indian J Pathol Microbiol 2020; 63 (04) 521-526
    CrossrefPubMedSearch in Google Scholar
  • 15 Koukourakis MI, Xanthopoulou E, Koukourakis IM. et al. Circulating plasma cell-free DNA (cfDNA) as a predictive biomarker for radiotherapy: results from a prospective trial in head and neck cancer. Cancer Diagn Progn 2023; 3 (05) 551-557
    CrossrefPubMedSearch in Google Scholar
  • 16 Mazurek AM, Rutkowski T, Fiszer-Kierzkowska A, Małusecka E, Składowski K. Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. Oral Oncol 2016; 54: 36-41
    CrossrefPubMedSearch in Google Scholar
  • 17 Basnet S, Zhang ZY, Liao WQ, Li SH, Li PS, Ge HY. The prognostic value of circulating cell-free DNA in colorectal cancer: a meta-analysis. J Cancer 2016; 7 (09) 1105-1113
    CrossrefPubMedSearch in Google Scholar
  • 18 Hovhannisyan G, Harutyunyan T, Aroutiounian R, Liehr T. The diagnostic, prognostic, and therapeutic potential of cell-free DNA with a special focus on COVID-19 and other viral infections. Int J Mol Sci 2023; 24 (18) 24
    CrossrefPubMedSearch in Google Scholar